Fred Turner - Built an a16z and YC-backed diagnostics (Dx) startup that built a CLIA lab that validated and launched an STD testing product scaling to test over 10,000 patients in medical centers across 5 states. Named one of top 100 practising scientists in the UK by UK Science Council 2013; studied biochemistry at Oxford.
Dr Jeffrey Klausner, MD - Dr. Klausner is a Professor of Medicine in the Division of Infectious Diseases and the Program in Global Health. Dr. Klausner earned his Medical Degree from Cornell University Medical College with Honors in Research. He completed his Residency in Internal Medicine at the New York University—Bellevue Hospital Center. Dr. Klausner earned his Master’s in Public Health with a focus on International Health and Epidemiology at the Harvard School of Public Health. After that training, Dr. Klausner was an Epidemic Intelligence Service Officer at the Centers for Disease Prevention and Control. Dr. Klausner completed his Fellowship in Infectious Diseases at the University of Washington, Seattle, under the mentorship of Prof. King Holmes.
From 1998-2009 Dr. Klausner was a Deputy Health Officer, Director of STD Prevention and Control Services at the San Francisco Department of Public Health, member of the UCSF School of Medicine faculty in the Divisions of AIDS and Infectious Diseases and Attending Physician at San Francisco General Hospital. From 2009-2011 Dr. Klausner was Branch Chief for HIV and TB at the Centers for Disease Control in Pretoria, South Africa, helping lead the South African PEPFAR program for care and treatment.
Dr Vlad Slepnev, PhD - Previously led teams that have built and launched 10 FDA-cleared diagnostic products in the infectious disease space. VP R&D at Meridian Biosciences (public Dx company) where he led development of 9 FDA cleared tests + 13 CE marked tests. Co-founder of Primera Dx, raised >$50M and sold to Qiagen. Yale + Pasteur Institute PostDoc. Publications in Cell, Science & Nature.
Dr Isaac Turner, PhD (no relation to Fred) - Dr Turner is a co-founder of Curative Inc, with a PhD in Bioinformatics from Oxford. He develops algorithms that make sense of very noisy data from Oxford Nanopore sequencers, enabling their potential use in sepsis diagnostics. Previously at an a16z-backed startup where he helped spin up a clinical lab offering novel antibiotic susceptibility tests. He led a team that scaled clinical data infrastructure quickly enabling them to close large healthcare providers as customers in the first 9 months of launching.